Table 1: Comparison of the similarities and differences of tandem-mass spectra of PSMA-617 and Imp. 2.
Figure 1: The synthetic scheme of PSMA-617 and drug of 175/177Lu-PSMA-617 [8].
Figure 2: Tandem-mass spectra at m/z of (a) 1042 and (b) 522. (c) The fragmentation pathways of PSMA-617.
Figure 3: Tandem-mass spectra at m/z of (a) 1215 and (b) 608. (c) The fragmentation pathways of Lu-PSMA-617.
Figure 4: Chromatograms of (a) purchased PSMA-617 reference standard, (b) homemade PSMA-617 product, and (c) Lu-PSMA-617.
Figure 5: (a) Molecular and fragmented ion mass spectra of impurity 1 at retention time tR of 5.83 min and (b) molecular fragmentation pathway.
Figure 6: Tandem-mass spectra of m/z = 1057 for Impurity 2 at retention time tR of 6.35 min in PSMA-617.
Figure 7: Supposed identity of Imp. 2 and its fragmented structures in synthetic PSMA-617 product.
Figure 8: Fragmented ion mass spectra at m/z = 307 and supposed metabolite identity by rat liver microsomes.
Figure 9: Fragmented ion mass spectra at m/z = 365 and supposed metabolite identity by rat liver microsomes
Figure 10: Fragmented ion mass spectra at m/z = 432 and supposed metabolite identity.
Figure 11: Fragmented ion mass spectra at m/z = 896 and supposed metabolite identity.
Figure 12: Fragmented ion mass spectra at m/z = 495 and supposed metabolite identity by rat kidney homogenate.
Figure 13: Fragmented ion mass spectra at m/z = 697 and supposed metabolite identity by rat kidney homogenate.
Figure 14: Metabolism study for Lu-PSMA-617 by rat liver microsomes and kidney homogenate.
Tables at a glance
Figures at a glance